Company Overview and News

Havilah Resources aims to put cobalt icing on its large South Australian copper cake

Havilah Resources Ltd (ASX:HAV) intends adding cobalt icing to its copper cake with appreciable cobalt resources in its sulphide copper projects in South Australia.

Havilah Resources acquires tenement strategic to iron ore and cobalt deposits

Havilah Resources Ltd (ASX:HAV) has acquired a tenement near Broken Hill of importance to its iron ore strategy and with potential to enhance its cobalt holdings.

Top 6 Cobalt Junior Developer Miners To Boom By 2021/2022

2018-05-17 seekingalpha
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.

Havilah Resources boosts gold resource and adds cobalt to the mix at North Portia

Havilah Resources Ltd (ASX:HAV) has added additional gold resources and a maiden cobalt resource to its North Portia project near the mining centre of Broken Hill.

Havilah Resources returns high-grade cobalt in samples from Scorpion prospect

Havilah Resources Ltd’s (ASX:HAV) sampling has returned high-grade cobalt from the Scorpion prospect within the Mutooroo Cobalt District in South Australia, near the mining centre of Broken Hill.

Cobalt Miners News For The Month Of April 2018

2018-04-25 seekingalpha
Cobalt miner news - South Korea's LG Chem to set up battery material JVs with China's Zhejiang Huayou Cobalt.

Havilah Resources and potential Chinese partner extend exclusivity period for copper-gold-cobalt project

Havilah Resources Ltd (ASX:HAV) and potential Chinese partner Wanbao Mining have extended the exclusivity period relating to the Kalkaroo Copper-Gold-Cobalt Project in South Australia.

A Look At The Junior Cobalt Miners In Early 2018

2018-04-17 seekingalpha
This article first appeared on Trend Investing on February 16, therefore all data is as of that date.

Havilah Resources transitions primary focus to copper with cobalt and gold as value-adds

Havilah Resources Ltd (ASX:HAV) is not resting on its laurels after transitioning from explorer to producer in 2016 and is transforming into a sizeable copper producer, supported by cobalt, gold molybdenum, tungsten and tin.

Havilah Resources obtains North Portia core samples for pre-feasibility study work

Havilah Resources Ltd (ASX:HAV) has completed two large diameter diamond core holes at the North Portia Copper-Gold Project in South Australia to provide samples for test work.

Cobalt Blue a major ASX success story in past 12 months … and it has a long way to run

Cobalt Blue Holdings Ltd (ASX:COB) has been a major ASX success story since listing early in 2017, riding high on the cobalt success story, which is based on the looming demand for lithium-ion batteries in the electric vehicle (EV) and energy storage markets.

Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.

Australia Mines Offers Nickel-Cobalt Exposure With Three Promising Projects In Australia

2018-03-21 seekingalpha
The Sconi resource estimate has 54,500 tonnes of contained cobalt with exploration upside. The Sconi project has recently secured 100% cobalt and nickel off-take.

Castillo Copper looks to fast-track cobalt exploration program nearby to Cobalt Blue's Thackaringa

Castillo Copper Ltd (ASX:CCZ) has received a report from its geology consultant, indicating anomalous cobalt occurrences across its Broken Hill Project.

Castillo Copper looks to fast track Broken Hill cobalt exploration program

Castillo Copper Ltd (ASX:CCZ) has received a report from its geology consultant, indicating anomalous cobalt occurrences across its Broken Hill asset.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...